Combined exposure of a selective JAK2 inhibitor BMS-911543 and TKIs eliminates IM-insensitive CML LSCs and their progenitor cells. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.